image330Susan P. Perrine, MD
Presidentand Chief Medical Officer                                 


Dr. Susan Perrine specializes in translating bench discoveries into clinical therapeutics for neglected and serious diseases. She has developed first-in-man therapiesand improved next generations of therapeutics, liaising with medicinaland physical chemistry,  formulation specialists, toxicology,and regulatory experts.  She has obtained Orphan Drug status for multiple therapeuticsand has 19 issued patents. Previously, as Chief Scientific Officer, VP Clinical Affairs of HemaQuest Pharmaceuticals, she directed international clinical trials, working with specialty clinical researchers in 7 countries. Dr. Perrine is also Professor of Medicine, Pediatrics, Pharmacologyand Experimental Therapeutics at Boston University Cancer Research Center. Her medicaland specialty training were from Tufts University School of Medicineand Tufts Medical Center, Harvard School of Public Health, Children’s Hospital Boston, Dana-Farber Cancer Institute,and Harvard Medical School.


Dr Douglas FallerDouglas V. Faller, MD, PhD

Chief Scientific Officer; Chairman, Scientific Advisory Board

Douglas V. Faller, MD, PhD,  inventor of the virologyand oncology technology platforms, has expertise across a broad range of molecularand cellular oncology, signaling, genetics,and clinical programs. He has developed novel approaches to disrupting the uncontrolled growth of multiple cancer types.  As Karin Grunebaum Professor for Cancer Research, Director of the Boston University Cancer Center, Vice-Chairman of the Department of Medicine, he directed basic scienceand  all oncology clinical trials for 25 years. Dr. Faller received his MD, PhDand subspeciality training at Harvard Medical School, MIT, the University of California San Francisco, Brighamand Women’s Hospital, Dana-Farber Cancer Institute, Boston Children’s Hospital, Harvard Medical School. Dr. Faller is a Scientific Co-founder of HemaQuest Pharmaceuticalsand Viracta Therapeutics. Dr. Faller is a Global Clinical Lead for Takeda Oncology.


John D. Schindler, Ph.D.
Vice-President, Clinicaland Regulatory Affairs  

John D. Schindler, Ph.D. is a veteran global pharmaceutical development executive, has filed 25 INDs, developed global regulatory strategy, directed clinical trialsand registered novel therapeutics in past positions including World Wide Medical Director at Biogen, Ortho Pharmaceuticals,and VP, Dallas Biomedical. Achievements include registration of the first monoclonal antibody OKT3, gamma interferon in Germany,and Erythropoietin in Europe. He has liaised between large pharma, CROs, CMOs, clinical researchers in the USand Europe. Dr. Schindler received his B.S. from Brown University,and his Ph.D. from the Massachusetts Institute of Technology.

David Fogel
Chief Business Officer and CFO  

James Remenick, PhD, JD
Intellectual Property Counsel

James Remenick, Ph.D., J.D. works strategically with Phoenicia to developand maximize the company’s valuable intellectual property rights, matching promising technology with concrete protection.  Dr. Remenickand the Firm of Remenick PLLC work with Phoenicia in all aspects of intellectual property protectionand enforcement including litigation, prosecution, licensing, opinions, consulting,and counseling. Dr. Remenick is admitted to the Bars of Washington, DC, Marylandand Texas,and is licensed to practice before the U.S. Patentand Trademark Office, multiple circuitand regional courtsand the US Supreme Court. Dr. Remenick received his J.D. from the American University, Washington College of Law, his Ph.D. from the Department of Microbiology of the Uniformed Services University of the Health Sciences,and was a researcher at the Laboratory of Molecular Virology of the National Cancer Institute at the National Institutes of Health.


Roger Frechette